Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | NEK2 | P51955 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12639920 | 0.86 | KDM4E (0.72) | KDM4ERXFP1TP53L3MBTL1MAPT | |
| SCHEMBL18395354 | 0.86 | KDM4E (0.68) | KDM4ERXFP1TP53L3MBTL1MAPT | |
| SCHEMBL17110169 | 0.82 | KMT2A (0.62) | KDM4EALDH1A1 | |
| SCHEMBL17110168 | 0.82 | KMT2A (0.62) | KDM4EALDH1A1 | |
| SCHEMBL13622622 | 0.80 | KDM4E (0.57) | KDM4ERXFP1TP53L3MBTL1MAPT | |
| SCHEMBL26863233 | 0.80 | KDM4E (0.59) | KDM4ERXFP1TP53L3MBTL1MAPT | |
| SCHEMBL11080229 | 0.79 | KDM4E (0.59) | KDM4ERXFP1TP53L3MBTL1MAPT | |
| SCHEMBL7880160 | 0.79 | KDM4E (0.74) | KDM4ERXFP1TP53L3MBTL1MAPT | |
| SCHEMBL29838723 | 0.79 | KDM4E (0.74) | KDM4ERXFP1TP53L3MBTL1MAPT | |
| SCHEMBL2274636 | 0.77 | KDM4E (0.66) | KDM4ECYP2C19L3MBTL1GPR119ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470524-B1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-8394834-B2 | Pyrrolidines as NK3 receptor antagonists | HOFFMAN-LA ROCHE INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8324250-B2 | Piperidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-12-04 | — | — | US | disclosed |
| EP-2470524-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| US-20110312941-A1 | 1,4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2011-12-22 | — | — | US | disclosed |
| US-20110312941-A1 | 1,4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2011-12-22 | — | — | US | disclosed |
| US-20110053948-A1 | PYRROLIDINES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2011-03-03 | — | — | US | disclosed |
| WO-2011023626-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | WO | disclosed |
| WO-2010097576-A9 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-10-07 | — | — | US | disclosed |
| WO-2010097576-A1 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053948-A1 | PYRROLIDINES AS NK3 RECEPTOR ANTAGONISTS | OPRM1, OPRK1, OPRL1 | KDM4E 3757/4885RXFP1 320/4885CYP2C19 2243/4885 |
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HTR3A, OPRL1, OPRK1 | KDM4E 2560/4885RXFP1 1717/4885CYP2C19 777/4885 |
| US-20110312941-A1 | 1,4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | AVPR2, AVPR1A, AVPR1B | KDM4E 2389/4885RXFP1 35/4885CYP2C19 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.